Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ventolin Nebules is a branded pharmaceutical formulation containing **salbutamol sulfate** (also known as albuterol in the United States), a rapid-onset, short-acting $\beta_2$-agonist (SABA). Developed by GSK, this product is delivered as a sterile nebulizer solution in single-dose ampules for inhalation. It functions by selectively stimulating $\beta_2$-adrenergic receptors in the lungs, which activates adenyl cyclase and increases intracellular cyclic AMP, leading to the relaxation of bronchial smooth muscle. It is a cornerstone therapy for the management and prevention of bronchospasm in patients with reversible obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), specifically for treating acute exacerbations and providing symptom relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ventolin Nebules.